日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Interstitial Lung Disease as a Late Occurrence in Ocrelizumab-Treated Patients With Multiple Sclerosis

间质性肺病是接受奥瑞珠单抗治疗的多发性硬化症患者的晚期并发症

Zurawska, Anna E; Cross, Anne H; Rzeszutek, Katarzyna; Rogozinska-Zawislak, Agnieszka; Selmaj, Krzysztof W

Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study

Ublituximab治疗多发性硬化症五年:ULTIMATE I 和 II 开放标签扩展研究

Cree, Bruce A C; Fox, Edward; Hartung, Hans-Peter; Alvarez, Enrique; Qian, Peiqing; Wray, Sibyl; Robertson, Derrick; Selmaj, Krzysztof; Wynn, Daniel; Mok, Koby; Rowland, Chris; Bodhinathan, Karthik; Sportelli, Peter; Miskin, Hari P; Steinman, Lawrence

Novel homozygous SYNE1 missense variant in late onset autosomal recessive cerebellar ataxia 1: a case report

一例晚发性常染色体隐性遗传性小脑共济失调1型中发现的新型纯合SYNE1错义变异:病例报告

Selmaj, Igor; Himmelreich, Nastassja; Selmaj, Krzysztof

A new, glycoengineered form of anti-CD20 monoclonal antibody, in treatment of multiple sclerosis

一种新型的、经糖基化改造的抗CD20单克隆抗体,用于治疗多发性硬化症

Selmaj, Krzysztof; Gold, Ralf; Selmaj, Igor; Mycko, Marcin P

De-escalating and discontinuing disease-modifying therapies in multiple sclerosis

多发性硬化症疾病修饰疗法的降级和停止

Androdias, Géraldine; Lünemann, Jan D; Maillart, Elisabeth; Amato, Maria Pia; Audoin, Bertrand; Bruijstens, Arlette L; Bsteh, Gabriel; Butzkueven, Helmut; Ciccarelli, Olga; Cobo-Calvo, Alvaro; Derfuss, Tobias; Di Pauli, Franziska; Edan, Gilles; Enzinger, Christian; Geraldes, Ruth; Granziera, Cristina; Hacohen, Yael; Hartung, Hans-Peter; Hynes, Sinéad; Inglese, Matilde; Kappos, Ludwig; Kuusisto, Hanna; Langer-Gould, Annette; Magyari, Melinda; Marignier, Romain; Montalban, Xavier; Mycko, Marcin P; Nourbakhsh, Bardia; Oh, Jiwon; Oreja-Guevara, Celia; Piehl, Fredrik; Prosperini, Luca; Sastre-Garriga, Jaume; Sellebjerg, Finn; Selmaj, Krzysztof; Siva, Aksel; Tallantyre, Emma; van Pesch, Vincent; Vukusic, Sandra; Weinstock-Guttman, Bianca; Zipp, Frauke; Tintoré, Mar; Iacobaeus, Ellen; Stankoff, Bruno

Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study

皮下注射奥克瑞珠单抗治疗多发性硬化症患者:OCARINA II 期 3 期研究结果

Newsome, Scott D; Krzystanek, Ewa; Selmaj, Krzysztof W; Dufek, Michal; Goldstick, Lawrence; Pozzilli, Carlo; Figueiredo, Catarina; Townsend, Ben; Kletzl, Heidemarie; Bortolami, Oscar; Zecevic, Dusanka; Giacobino, Caroline; Clinch, Susanne; Shen, Yun-An; Bhullar, Gurpreet Deol; Schneble, Hans-Martin; Centonze, Diego

Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials

奥扎尼莫德治疗复发型多发性硬化症患者的脑萎缩及其与长期残疾和认知功能的关系:来自 3 期和开放标签扩展试验的结果

Cohen, Jeffrey A; Arnold, Douglas L; DeLuca, John; Hartung, Hans-Peter; Kappos, Ludwig; Comi, Giancarlo; Selmaj, Krzysztof; Steinman, Lawrence; Bar-Or, Amit; Montalban, Xavier; Havrdová, Eva K; Sheffield, James K; Pachai, Chahin; Cheng, Chun-Yen; Riolo, Jon V; Cree, Bruce Ac

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial

奥扎尼莫德治疗复发型多发性硬化症的长期安全性和有效性:DAYBREAK开放标签扩展试验的最终分析

Selmaj, Krzysztof W; Steinman, Lawrence; Comi, Giancarlo; Bar-Or, Amit; Arnold, Douglas L; Hartung, Hans-Peter; Montalbán, Xavier; Havrdová, Eva K; Sheffield, James K; Krakovich, Anthony; Cheng, Chun-Yen; Riolo, Jon V; Pachai, Chahin; Thorpe, Andrew; DeBoer, Erik; Kappos, Ludwig; Cohen, Jeffrey A; Cree, Bruce Ac

Identifying Biomarkers for Remyelination and Recovery in Multiple Sclerosis: A Measure of Progress

识别多发性硬化症髓鞘再生和恢复的生物标志物:衡量进展

Ricigliano, Vito A G; Marenna, Silvia; Borrelli, Serena; Camera, Valentina; Carnero Contentti, Edgar; Szejko, Natalia; Bakirtzis, Christos; Gluscevic, Sanja; Samadzadeh, Sara; Hartung, Hans-Peter; Selmaj, Krzysztof; Stankoff, Bruno; Comi, Giancarlo; Ecf Young Investigators/Fellows Initiative

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

阿仑单抗与干扰素β1a作为复发缓解型多发性硬化症患者一线治疗的比较:一项随机对照 3 期试验

Jeffrey A Cohen, Alasdair J Coles, Douglas L Arnold, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner, Elizabeth Fisher, Vesna V Brinar, Gavin Giovannoni, Miroslav Stojanovic, Bella I Ertik, Stephen L Lake, David H Margolin, Michael A Panzara,